Agree Realty Supports Thousand Oaks Biologics in Achieving EU GMP Compliance for ADC Manufacturing
- Thousand Oaks Biologics achieved EU GMP compliance for its ADC manufacturing site in Shanghai after a successful QP audit.
- The certification enhances Thousand Oaks Biologics' competitiveness and supports global supply chain access for domestic innovators.
- The company plans to expand its ADC technology and manufacturing capacity, contributing to innovative medicines and global business development.
Thousand Oaks Biologics Achieves EU GMP Compliance for ADC Manufacturing
Thousand Oaks Biologics, a leading player in the biopharmaceutical sector, marks a significant milestone with the successful completion of a European Union Qualified Person (QP) audit of its antibody-drug conjugate (ADC) manufacturing site in Shanghai. Conducted over five days in July 2025, the rigorous assessment confirms that the facility meets EU Good Manufacturing Practice (GMP) standards, earning a coveted QP Declaration. This certification not only establishes Thousand Oaks Biologics as one of the select Contract Development and Manufacturing Organizations (CDMOs) in China providing international ADC services but also enhances the overall competitiveness of Chinese CDMOs on the global stage.
The audit evaluated various critical aspects of the manufacturing process, including facilities, equipment, material controls, and the pivotal steps involved in upstream drug substance production and quality control testing. The inspection team praised the state-of-the-art facilities and stringent quality management systems in place, underscoring the company's commitment to maintaining high standards of quality and safety in drug development. With the EU QP system recognized globally as a benchmark for pharmaceutical quality assurance since its establishment in 1975, Thousand Oaks Biologics' achievement is expected to facilitate domestic innovators in the ADC field to access global supply chains, thereby promoting innovation in the biopharmaceutical landscape.
Looking ahead, Thousand Oaks Biologics plans to leverage this certification to expand its ADC technology platforms, enhance GMP-compliant manufacturing capacity, and optimize production processes. The company's strategy focuses on delivering integrated, high-quality services that span early-stage research and development through to commercial manufacturing. This holistic approach not only aims to contribute to the creation of innovative medicines for patients worldwide but also accelerates Thousand Oaks Biologics' global business development initiatives, positioning the company as a key player in the evolving biopharmaceutical market.
In related industry developments, Ona Therapeutics appoints Dr. Antoine Yver as Chair of its Board of Directors, bringing over 35 years of oncology drug development experience to the company. Dr. Yver's leadership is expected to be pivotal as Ona transitions into a clinical-stage organization, particularly in advancing its lead ADC, ONA-255, for breast cancer treatment.
Related Cashu News

Lamar Advertising Co Moves to Value Indices Amid Shift in Investment Strategies
Lamar Advertising Co (Ticker: LAMR) has recently undergone a significant change in its market classification by being added to several Russell value and defensive indices. This inclusion reflects a sh…

Alexandria Real Estate Equities Advances Corporate Responsibility and Strengthens Its Position in Life Sciences
Alexandria Real Estate Equities (ARE) has made significant strides in enhancing its corporate responsibility efforts, as detailed in its recently published 2025 Corporate Responsibility Report. The re…

Healthpeak OP LLC Achieves Key Index Inclusion, Boosting Investor Interest and Trading Activity
Healthpeak OP LLC (Ticker: DOC) leverages significant market developments to reinforce its position in the real estate investment trust sector through strategic index inclusion, which may reshape inve…

Public Storage Boosts Financial Flexibility with New Credit Facility and Commercial Paper Program
Public Storage (Ticker: PSA) enhances its financial flexibility with a new unsecured credit facility and commercial paper program. Strategic Financial Innovations The company announces the closure of…

